Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of “Moderate Buy” from Analysts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been assigned a consensus rating of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $86.71.

Several equities analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $115.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 12th. The Goldman Sachs Group raised Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and increased their price target for the stock from $56.00 to $67.00 in a research report on Thursday, June 6th. Bank of America cut their price target on Ultragenyx Pharmaceutical from $83.00 to $76.00 and set a “buy” rating on the stock in a research report on Friday, May 31st. Wedbush increased their price target on Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the stock a “neutral” rating in a research report on Friday, May 31st. Finally, TD Cowen increased their price target on Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th.

Insider Activity

In related news, EVP Karah Herdman Parschauer sold 9,806 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $45.00, for a total value of $441,270.00. Following the transaction, the executive vice president now directly owns 57,981 shares of the company’s stock, valued at approximately $2,609,145. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, EVP Karah Herdman Parschauer sold 9,806 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $45.00, for a total value of $441,270.00. Following the transaction, the executive vice president now directly owns 57,981 shares of the company’s stock, valued at approximately $2,609,145. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Corazon (Corsee) D. Sanders sold 1,737 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $41.10, for a total transaction of $71,390.70. Following the completion of the transaction, the director now directly owns 7,248 shares in the company, valued at $297,892.80. The disclosure for this sale can be found here. Insiders have sold 11,685 shares of company stock worth $518,923 in the last ninety days. Company insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Franklin Resources Inc. lifted its stake in Ultragenyx Pharmaceutical by 13.3% in the 4th quarter. Franklin Resources Inc. now owns 214,738 shares of the biopharmaceutical company’s stock worth $10,269,000 after purchasing an additional 25,144 shares in the last quarter. Rafferty Asset Management LLC lifted its stake in Ultragenyx Pharmaceutical by 21.2% in the 4th quarter. Rafferty Asset Management LLC now owns 221,910 shares of the biopharmaceutical company’s stock worth $10,612,000 after purchasing an additional 38,859 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Ultragenyx Pharmaceutical by 5.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 396,725 shares of the biopharmaceutical company’s stock worth $14,143,000 after purchasing an additional 19,487 shares in the last quarter. New York State Common Retirement Fund lifted its stake in Ultragenyx Pharmaceutical by 37.0% in the 4th quarter. New York State Common Retirement Fund now owns 72,866 shares of the biopharmaceutical company’s stock worth $3,484,000 after purchasing an additional 19,673 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its stake in Ultragenyx Pharmaceutical by 42.5% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 57,000 shares of the biopharmaceutical company’s stock worth $2,745,000 after purchasing an additional 17,000 shares in the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE opened at $41.10 on Friday. The stock’s fifty day moving average price is $41.29 and its 200 day moving average price is $45.06. Ultragenyx Pharmaceutical has a 1 year low of $31.52 and a 1 year high of $54.56. The company has a market cap of $3.42 billion, a price-to-earnings ratio of -5.12 and a beta of 0.60.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.72) by ($0.31). Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 425.63%. The firm had revenue of $108.83 million during the quarter, compared to analyst estimates of $116.03 million. During the same period in the previous year, the company earned ($2.33) earnings per share. Ultragenyx Pharmaceutical’s revenue was up 8.3% on a year-over-year basis. Research analysts expect that Ultragenyx Pharmaceutical will post -6.43 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.